novo-holdings
(3)
Doctor Anywhere
Doctor Anywhere is a Singapore-headquartered, tech-led healthcare company founded in 2017 by Lim Wai Mun. It started as a telemedicine app that put a licensed doctor on a video call within minutes, then deliberately grew downward into the physical world - GP clinics, specialist practices, health screening and imaging suites, home visits, medication delivery and an in-app health marketplace. The company describes the result as a 'Hospital Anywhere' model: one app that carries a patient from a 2am sore throat to a knee surgeon, across Singapore, Malaysia, Thailand, Indonesia and the Philippines. It serves roughly 3 million users, sells to consumers, corporates and insurers, and has raised about US$176 million from investors including Asia Partners, Novo Holdings, Square Peg, EDBI, IHH Healthcare, Philips and Pavilion Capital.
Kivu Bioscience
Kivu Bioscience is a clinical-stage biotechnology company in San Mateo, California, building next-generation antibody-drug conjugates (ADCs) for solid tumors. Founded by BioGeneration Ventures and led by ADC veteran Mohit Trikha, the company licenses Synaffix's GlycoConnect and HydraSpace site-specific conjugation technology to engineer more homogeneous, stable ADCs that aim to widen the therapeutic window - hitting tumors harder while sparing healthy tissue. Backed by a $92 million Series A led by Novo Holdings, Kivu has moved its lead candidates KIVU-107 (PTK7) and KIVU-305 (CEACAM5) into Phase 1 clinical trials.
Andrew Schiermeier
Andrew Schiermeier is the President and CEO of AvenCell Therapeutics, a clinical-stage biotech in Cambridge, Massachusetts and Dresden, Germany building switchable, universal CAR-T cell therapies for hard-to-treat cancers like acute myeloid leukemia. An engineer-turned-operator with a Harvard PhD in applied mathematics, he spent two decades across startups and global pharma - five years at CRISPR pioneer Intellia Therapeutics rising to COO, and a stint running Merck KGaA's oncology business across 60-plus countries - before taking AvenCell's helm in 2021 and leading its $112 million Series B in 2024.